Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Boris A Hadaschik

Showing results (41-50 of 125) with videos related to

Pageof 13
Sort By:
Clinical Nuclear Medicine|September 9, 2016
68Ga-PSMA-11 Dynamic PET/CT Imaging in Primary Prostate CancerChristos Sachpekidis, Klaus Kopka, Matthias Eder, et al.
BJU International|November 15, 2008
Paclitaxel incorporated in hydrophobically derivatized hyperbranched polyglycerols for intravesical bladder cancer therapyClement Mugabe, Boris A Hadaschik, Rajesh K Kainthan, et al.
Urologia Internationalis|April 18, 2023
MR-Guided Transurethral Ultrasound Ablation of Prostate Cancer: Initial Experience of Monitoring Tumor Response by Dynamic Apparent Diffusion Coefficient Measurements at 3.0 TLena Meyer, Andreas Bohlscheid, Oscar Lemmer, et al.
Advances in Therapy|November 19, 2021
Apalutamide Compared with Darolutamide for the Treatment of Non-metastatic Castration-Resistant Prostate Cancer: Efficacy and Tolerability in a Matching-Adjusted Indirect ComparisonSimon Chowdhury, Stephane Oudard, Hiroji Uemura, et al.
Advances in Anatomic Pathology|October 12, 2022
Immune-Checkpoint-Inhibitor Therapy-Principles and Relevance of Biomarkers for Pathologists and OncologistsChristopher Darr, Thomas Hilser, Claudia Kesch, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 8, 2017
The Clinical Impact of Additional Late PET/CT Imaging with <sup>68</sup>Ga-PSMA-11 (HBED-CC) in the Diagnosis of Prostate CancerAli Afshar-Oromieh, Lars Peter Sattler, Walter Mier, et al.
BJU International|August 14, 2013
Histology core-specific evaluation of the European Society of Urogenital Radiology (ESUR) standardised scoring system of multiparametric magnetic resonance imaging (mpMRI) of the prostateTimur H Kuru, Matthias C Roethke, Philip Rieker, et al.
Urologie (Heidelberg, Germany)|March 21, 2023
[Systematic or targeted fusion-guided biopsy]Analena Elisa Handke, Peter Albers, Lars Schimmöller, et al.
Cancer Research|June 19, 2008
Oncolytic vesicular stomatitis viruses are potent agents for intravesical treatment of high-risk bladder cancerBoris A Hadaschik, Kaixin Zhang, Alan I So, et al.
BJU International|April 4, 2008
Paclitaxel and cisplatin as intravesical agents against non-muscle-invasive bladder cancerBoris A Hadaschik, Melanie G ter Borg, John Jackson, et al.
Pageof 13

Showing results (41-50 of 125) with videos related to

Sort By:
Pageof 13
Clinical Nuclear Medicine|September 9, 2016
68Ga-PSMA-11 Dynamic PET/CT Imaging in Primary Prostate CancerChristos Sachpekidis, Klaus Kopka, Matthias Eder, et al.
BJU International|November 15, 2008
Paclitaxel incorporated in hydrophobically derivatized hyperbranched polyglycerols for intravesical bladder cancer therapyClement Mugabe, Boris A Hadaschik, Rajesh K Kainthan, et al.
Urologia Internationalis|April 18, 2023
MR-Guided Transurethral Ultrasound Ablation of Prostate Cancer: Initial Experience of Monitoring Tumor Response by Dynamic Apparent Diffusion Coefficient Measurements at 3.0 TLena Meyer, Andreas Bohlscheid, Oscar Lemmer, et al.
Advances in Therapy|November 19, 2021
Apalutamide Compared with Darolutamide for the Treatment of Non-metastatic Castration-Resistant Prostate Cancer: Efficacy and Tolerability in a Matching-Adjusted Indirect ComparisonSimon Chowdhury, Stephane Oudard, Hiroji Uemura, et al.
Advances in Anatomic Pathology|October 12, 2022
Immune-Checkpoint-Inhibitor Therapy-Principles and Relevance of Biomarkers for Pathologists and OncologistsChristopher Darr, Thomas Hilser, Claudia Kesch, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 8, 2017
The Clinical Impact of Additional Late PET/CT Imaging with <sup>68</sup>Ga-PSMA-11 (HBED-CC) in the Diagnosis of Prostate CancerAli Afshar-Oromieh, Lars Peter Sattler, Walter Mier, et al.
BJU International|August 14, 2013
Histology core-specific evaluation of the European Society of Urogenital Radiology (ESUR) standardised scoring system of multiparametric magnetic resonance imaging (mpMRI) of the prostateTimur H Kuru, Matthias C Roethke, Philip Rieker, et al.
Urologie (Heidelberg, Germany)|March 21, 2023
[Systematic or targeted fusion-guided biopsy]Analena Elisa Handke, Peter Albers, Lars Schimmöller, et al.
Cancer Research|June 19, 2008
Oncolytic vesicular stomatitis viruses are potent agents for intravesical treatment of high-risk bladder cancerBoris A Hadaschik, Kaixin Zhang, Alan I So, et al.
BJU International|April 4, 2008
Paclitaxel and cisplatin as intravesical agents against non-muscle-invasive bladder cancerBoris A Hadaschik, Melanie G ter Borg, John Jackson, et al.
Pageof 13